论文部分内容阅读
In the past 10 years,over 490 clinical trials of more than 20 HDACs inhibitors(HDACIs)candidates have been initiated,culminating in the approval of three anti-tumor drugs vorinostat(SAHA),romidepsin(FK228)and Resminostat(4SC-201).In our previous study,we designed and synthesized a novel series of N-hydroxycinnamamide-based HDACIs combining indole bioactive fragment1.Further derivatization of these compounds led to a series of more potent N-hydroxycinnamamide-based HDACIs with promising in vivo antitumour activity.